MPO
Myeloperoxidase
Also known as: PERM_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P05164
- Gene
- MPO
- Ensembl
- ENSG00000005381
- Chromosome
- 17
- Canonical length
- 745 aa
- Protein class
- Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Vesicles
- Secretome location
- Intracellular and membrane
- Quaternary structure
- Homodimer
OverviewNCBI Gene
Myeloperoxidase (MPO) is a heme protein synthesized during myeloid differentiation that constitutes the major component of neutrophil azurophilic granules. Produced as a single chain precursor, myeloperoxidase is subsequently cleaved into a light and heavy chain. The mature myeloperoxidase is a tetramer composed of 2 light chains and 2 heavy chains. This enzyme produces hypohalous acids central to the microbicidal activity of neutrophils. [provided by RefSeq, Nov 2014]
Canonical amino-acid sequenceUniProt
745 residues, UniProt reviewed canonical sequence.
>P05164|MPO
1 MGVPFFSSLR CMVDLGPCWA GGLTAEMKLL LALAGLLAIL ATPQPSEGAA PAVLGEVDTS
61 LVLSSMEEAK QLVDKAYKER RESIKQRLRS GSASPMELLS YFKQPVAATR TAVRAADYLH
121 VALDLLERKL RSLWRRPFNV TDVLTPAQLN VLSKSSGCAY QDVGVTCPEQ DKYRTITGMC
181 NNRRSPTLGA SNRAFVRWLP AEYEDGFSLP YGWTPGVKRN GFPVALARAV SNEIVRFPTD
241 QLTPDQERSL MFMQWGQLLD HDLDFTPEPA ARASFVTGVN CETSCVQQPP CFPLKIPPND
301 PRIKNQADCI PFFRSCPACP GSNITIRNQI NALTSFVDAS MVYGSEEPLA RNLRNMSNQL
361 GLLAVNQRFQ DNGRALLPFD NLHDDPCLLT NRSARIPCFL AGDTRSSEMP ELTSMHTLLL
421 REHNRLATEL KSLNPRWDGE RLYQEARKIV GAMVQIITYR DYLPLVLGPT AMRKYLPTYR
481 SYNDSVDPRI ANVFTNAFRY GHTLIQPFMF RLDNRYQPME PNPRVPLSRV FFASWRVVLE
541 GGIDPILRGL MATPAKLNRQ NQIAVDEIRE RLFEQVMRIG LDLPALNMQR SRDHGLPGYN
601 AWRRFCGLPQ PETVGQLGTV LRNLKLARKL MEQYGTPNNI DIWMGGVSEP LKRKGRVGPL
661 LACIIGTQFR KLRDGDRFWW ENEGVFSMQQ RQALAQISLP RIICDNTGIT TVSKNNIFMS
721 NSYPRDFVNC STLPALNLAS WREASLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MPO can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.23
- Highest tissue expression
- 3,250 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 3,250 nTPM
- spleen: 21 nTPM
- salivary gland: 9.9 nTPM
- lung: 8.1 nTPM
- thymus: 6.9 nTPM
- skin: 3.7 nTPM
Single-cell type
- monocyte progenitors: 2,629 nCPM
- neutrophil progenitors: 2,272 nCPM
- erythrocytes: 40 nCPM
- hematopoietic stem cells: 32 nCPM
- megakaryocytes: 25 nCPM
- megakaryocyte-erythroid progenitors: 18 nCPM
Immune cell
- total PBMC: 6.3 nTPM
- classical monocyte: 1.2 nTPM
- myeloid DC: 0.7 nTPM
- intermediate monocyte: 0.6 nTPM
- neutrophil: 0.1 nTPM
- non-classical monocyte: 0.1 nTPM
Brain region
- midbrain: 0.5 nTPM
- cerebral cortex: 0.4 nTPM
- hypothalamus: 0.4 nTPM
- medulla oblongata: 0.4 nTPM
- pons: 0.4 nTPM
- thalamus: 0.4 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about MPO.
Disease | AllUniProt
Conditions MPO is implicated in, by any mechanism.
- Myeloperoxidase deficiency (MPOD) MIM:254600
Disease | GeneticClinVar
16 pathogenic / likely-pathogenic of 159 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Myeloperoxidase deficiency
- MPO-related disorder
- Alzheimer disease type 1
- Acute myeloid leukemia
Disease | ImmuneIEDB
Conditions an epitope on MPO was assayed in.
- rheumatoid arthritis B and T cell
- systemic scleroderma B cell
- autoimmune vasculitis B and T cell
- osteoarthritis B cell
- acute myeloid leukemia T cell
Disease | AutoantibodyPubMed
Conditions in which antibodies against MPO are reported. Each links to that disease's full target list.
- Vasculitis 167
- Glomerulonephritis 158
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 106
- Granulomatosis with Polyangiitis 74
- Lupus Erythematosus, Systemic 33
- Scleroderma, Systemic 24
- Kidney Diseases 21
- Glomerulonephritis, IGA 17
- Arthritis, Rheumatoid 14
- Anti-Glomerular Basement Membrane Disease 13
- Acute Kidney Injury 11
- Lung Diseases, Interstitial 11
- Graves Disease 10
- Colitis, Ulcerative 9
- Renal Insufficiency 9
- Arthritis 8
- Lupus Nephritis 7
- Glomerulonephritis, Membranous 6
- Kidney Failure, Chronic 6
- Nephritis 6
Showing 20 of 49 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for MPO from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
612 publications
- Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice.
2002 · J Clin Invest · RCR 19.3 · 868 citations - Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients.
1999 · Arthritis Rheum · RCR 17.5 · 520 citations - Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome.
2005 · Arthritis Rheum · RCR 14.1 · 467 citations - Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies.
2007 · Am J Pathol · RCR 11.4 · 462 citations - C5a receptor (CD88) blockade protects against MPO-ANCA GN.
2014 · J Am Soc Nephrol · RCR 9.3 · 280 citations
Show 20 more of 612 total
- Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders.
1992 · Am J Med · RCR 9.1 · 232 citations - Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies.
2000 · Arthritis Rheum · RCR 8.7 · 259 citations - Association of autoantibodies to myeloperoxidase with different forms of vasculitis.
1990 · Arthritis Rheum · RCR 7.9 · 196 citations - Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells.
1992 · Kidney Int · RCR 7.6 · 241 citations - Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus.
1990 · Clin Exp Immunol · RCR 7.4 · 165 citations - Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells.
1992 · Am J Pathol · RCR 7.4 · 246 citations - ANCA and associated diseases: immunodiagnostic and pathogenetic aspects.
1993 · Clin Exp Immunol · RCR 7.4 · 206 citations - A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease.
1990 · Immunobiology · RCR 7.3 · 217 citations - Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease.
1997 · Ann Intern Med · RCR 7.3 · 192 citations - Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis.
2014 · J Am Soc Nephrol · RCR 6.9 · 209 citations - Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis.
2013 · J Clin Invest · RCR 6.7 · 204 citations - Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: a multicentre real-world study.
2025 · Rheumatology (Oxford) · RCR 6.3 · 17 citations - Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role.
1992 · Gut · RCR 6.3 · 166 citations - The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition.
1996 · Arch Intern Med · RCR 5.6 · 132 citations - The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis.
2021 · Autoimmun Rev · RCR 5.5 · 64 citations - The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies.
2005 · Am J Pathol · RCR 5.4 · 241 citations - Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.
2005 · Nephrol Dial Transplant · RCR 5.4 · 201 citations - Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease.
2011 · Clin J Am Soc Nephrol · RCR 5.3 · 133 citations - Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo.
2005 · Blood · RCR 5.2 · 214 citations - Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice.
2007 · Kidney Int · RCR 5.1 · 213 citations
Reference: B cellIEDB
6 publications
- Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis.
2017 · Sci Immunol · RCR 9.4 · 262 citations - Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis.
2013 · J Clin Invest · RCR 6.7 · 204 citations - Disordered Antigens and Epitope Overlap Between Anti-Citrullinated Protein Antibodies and Rheumatoid Factor in Rheumatoid Arthritis.
2020 · Arthritis Rheumatol · RCR 1.7 · 30 citations - Restricted myeloperoxidase epitopes drive the adaptive immune response in MPO-ANCA vasculitis.
2020 · J Autoimmun · RCR 1.6 · 29 citations - Computational analysis of high-density peptide microarray data with application from systemic sclerosis to multiple sclerosis.
2012 · Autoimmun Rev · RCR 1 · 35 citations
Show 1 more
- Epitope specificity of myeloperoxidase antibodies: identification of candidate human immunodominant epitopes.
2011 · Clin Exp Immunol · RCR 0.6 · 21 citations
Reference: T cellIEDB
4 publications
- Isolation of HLA-DR-naturally presented peptides identifies T-cell epitopes for rheumatoid arthritis.
2022 · Ann Rheum Dis · RCR 1.1 · 14 citations - Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes.
2014 · Proc Natl Acad Sci U S A · RCR 0.6 · 29 citations - Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells.
2014 · Leukemia · RCR 0.6 · 23 citations - Novel myeloperoxidase-derived HLA-A2-restricted peptides as therapeutic targets against myeloid leukemia.
2021 · Cytotherapy · RCR 0.1 · 2 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.15
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.32
- DepMap mean gene effect
- -0.13
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- defense response
- defense response to bacterium
- defense response to fungus
- hydrogen peroxide catabolic process
- low-density lipoprotein particle remodeling
- negative regulation of apoptotic process
- removal of superoxide radicals
- respiratory burst involved in defense response
- response to food
- response to gold nanoparticle
- response to lipopolysaccharide
- response to mechanical stimulus
- response to oxidative stress
- response to yeast
- hypochlorous acid biosynthetic process
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of MPO in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MPO as an antibody target. Whether an autoantibody or antibody against MPO could matter depends on whether native MPO is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MPO is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MPO as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...